
Galectin Therapeutics Inc GALT.OQ GALT.O is expected to report results on May 13 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Galectin Therapeutics Inc is for a loss of 20 cents per share.
The one available analyst rating on the shares is "hold".
The mean earnings estimate of analysts was unchanged in the last three months.
This summary was machine generated May 9 at 14:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)